MMP9 and metabolic syndrome: MMP-9 concentrations were lower among patients with inactive TED, formally diagnosed with dyslipidemia and on HMG-CoA (3-hydroxy-3-methyl glutaryl-CoA) reductase inhibitors (523.47 ± 303.58 vs. 1,860.44 ± 1,442.38; P = 0.0250).